The global NASH market size was valued at USD 9.26 billion in 2025 and is projected to grow from USD 11.45 billion in 2026 to USD 62.61 billion by 2034, registering a CAGR of 23.66% during the forecast period (2026–2034). North America dominated the NASH market with a market share of 74.12% in 2025.
Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease characterized by liver inflammation, fat accumulation, and fibrosis. The condition is closely associated with obesity, type 2 diabetes, metabolic syndrome, and other lifestyle related disorders.
The NASH market demand is driven by the rising burden of obesity and diabetes, growing awareness of liver health, and the introduction of novel treatment options. Increasing research investments, expanding clinical pipelines, supportive regulatory initiatives, and improved diagnostic capabilities are also contributing to NASH market growth.
Download a Free Sample To learn more about this report,
The NASH market is indirectly exposed to supply chain disruptions due to its dependence on pharmaceutical manufacturing, active pharmaceutical ingredients, clinical trial materials, and specialized diagnostic technologies. Disruptions in raw material sourcing, contract manufacturing, logistics, and global distribution networks can delay drug development, regulatory submissions, and commercial product availability, impacting treatment access across multiple regions. Despite these challenges, the market is expected to follow a capacity-constrained recovery, supported by supply chain diversification, increased manufacturing investments, and strengthening pharmaceutical production capabilities.
Growing Adoption of Combination Therapies for Improved Disease Management
The increasing complexity of NASH treatment is driving the transition from single-drug approaches to combination therapies targeting multiple disease pathways, including inflammation, fibrosis, and metabolic dysfunction. Pharmaceutical companies are advancing combination regimens to improve therapeutic efficacy and patient outcomes while addressing different stages of disease progression. This trend is strengthening clinical development pipelines and expanding treatment possibilities for patients with advanced liver disease.
Increasing Integration of Non-invasive Diagnostic Technologies into Clinical Care
The growing need for early disease detection is accelerating the transition from liver biopsy toward non-invasive diagnostic tools such as imaging techniques and blood-based biomarkers. Healthcare providers are increasingly adopting these technologies to improve patient identification, monitor disease progression, and support timely treatment decisions. For instance, Echosens' FibroScan is widely used to assess liver fibrosis and steatosis in patients with suspected NASH.
The NASH (MASH) market forecasts investments directed toward the development of combination therapies, next-generation metabolic drug candidates, RNA-based therapeutics, biomarker discovery, and non-invasive diagnostic technologies to improve disease detection and treatment outcomes. In July 2025, Madrigal secured a USD 350 million term loan facility with access to an additional USD 150 million delayed-draw facility and up to USD 250 million incremental financing to support commercialization of Rezdiffra and expansion of its MASH pipeline.
Advancements in Late Stage Drug Development and Rising Complexity of High Blood-Loss Surgical Procedures Drives Market
The advancement of Phase III drug candidates is strengthening confidence in the NASH treatment landscape, driving market demand and investment. Pharmaceutical companies are expanding late-stage clinical programs to develop therapies that target liver fibrosis, inflammation, and metabolic dysfunction, improving future treatment availability. This is accelerating commercialization strategies, strategic collaborations, and manufacturing preparedness across the industry.
The increasing volume of complex cardiovascular, transplant, major orthopedic, and aortic surgeries is creating demand for advanced autotransfusion technologies capable of managing substantial intraoperative blood loss. These procedures often require rapid blood recovery and reinfusion to maintain hemodynamic stability while reducing dependence on donor blood supplies. As surgical techniques become more sophisticated and intervention complexity rises, healthcare facilities are investing in specialized blood salvage systems to support efficient perioperative blood management and procedural continuity.
Limited Patient Identification and Lack of Disease-specific Treatment Options Restrain Market Expansion
The limited diagnosis of NASH due to asymptomatic disease progression and dependence on specialized diagnostic methods restricts the identification of eligible patients for treatment. Many cases remain undetected until advanced stages, reducing treatment uptake and slowing commercialization opportunities for emerging therapies.
The absence of multiple approved therapies addressing different stages and mechanisms of NASH limits treatment flexibility and reduces broader clinical adoption. Many emerging therapies focus on specific disease pathways, while patients often require comprehensive management of metabolic conditions, fibrosis progression, and liver inflammation.
Expansion of Precision Medicine Approaches and Increasing Adoption of Digital Liver Health Platforms Offer Growth Opportunities to Market Players
The increasing use of biomarker-driven patient segmentation creates growth opportunities for pharmaceutical companies developing targeted NASH therapies. Precision medicine approaches can help identify patients based on fibrosis stage, metabolic profile, and disease characteristics, improving treatment selection and clinical outcomes. Companies such as Novo Nordisk, Eli Lilly, and Boehringer Ingelheim are investing in advanced metabolic and liver disease pipelines that support personalized treatment strategies. This opportunity is expected to expand as healthcare providers move toward more individualized NASH management models.
The increasing integration of artificial intelligence, digital health platforms, and remote monitoring tools creates growth opportunities for companies developing solutions that improve NASH screening, progression tracking, and patient management. These technologies can support earlier intervention by combining clinical data, imaging results, and metabolic indicators for more efficient disease monitoring. This opportunity is expected to expand as healthcare systems focus on scalable approaches for managing the growing burden of metabolic liver diseases.
Balancing Safety and Efficacy Profiles and Integrating NASH Therapies into Existing Metabolic Disease Treatment Pathways Challenges Market Growth
The development of NASH therapies requires achieving meaningful improvements in liver fibrosis while maintaining acceptable safety profiles, particularly among patients with obesity, diabetes, and cardiovascular risks. Balancing therapeutic effectiveness with tolerability remains a challenge for companies advancing novel mechanisms. For example, several investigational NASH candidates have faced setbacks due to safety concerns or insufficient efficacy signals during clinical development, affecting confidence in certain treatment approaches.
The overlap between NASH, obesity, diabetes, and cardiovascular disorders creates challenges in defining treatment pathways and positioning NASH-specific therapies within existing clinical practices. Healthcare providers need to determine when to initiate liver-directed treatments alongside metabolic disease management, which can slow adoption. This complexity requires companies to generate clinical evidence supporting how NASH therapies complement existing metabolic interventions.
The GLP-1 agonist segment accounted for a share of 31.24% in 2025, owing to their ability to promote weight reduction, improve insulin resistance, and regulate metabolic dysfunction linked with liver fat accumulation. Its increasing adoption in obesity and diabetes management supports broader clinical interest for NASH treatment applications.
The thiazolidinediones segment is expected to grow at a CAGR of around 24.17% during the forecast period due to their role in improving insulin sensitivity, enhancing adipocyte function, and reducing hepatic steatosis. Its potential application in patients with metabolic syndrome-associated NASH supports continued research and therapeutic development.
Request Customizationto receive a tailored report.
The stage 1 segment accounted for a share of 35.72% in 2025 due to increasing identification of early liver fat accumulation, growing metabolic disease screening, and rising awareness of preventing NASH progression. Early intervention strategies are encouraging healthcare providers to monitor patients before significant fibrosis develops.
The stage 2 segment is expected to grow at a CAGR of 17.65 during the forecast period, driven by increasing demand for fibrosis focused treatments, greater use of liver imaging technologies, and rising clinical attention toward patients with moderate disease progression. This stage represents a key treatment window before advanced liver damage occurs.
The hospital pharmacies segment accounted for a share of 64.10% in 2025 due to the requirement for specialist consultation, supervised treatment initiation, and integration with hepatology and metabolic disease management programs. Hospitals remain the primary channel for patients undergoing advanced diagnostics and physician-guided NASH treatment planning.
The specialty pharmacies segment is expected to grow at a CAGR of 24.80% during the forecast period, driven by increasing demand for complex medication support, patient adherence management services, and coordinated therapy access programs. Specialty pharmacies are becoming important as emerging NASH therapies require structured monitoring and long-term patient support.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by High Metabolic Disease Burden and Strong Pharmaceutical Innovation Ecosystem
The North America NASH market accounted for the largest regional share of 74.12% in 2025, driven by rising prevalence of obesity, type 2 diabetes, and metabolic disorders, along with strong adoption of advanced diagnostic approaches and innovative liver disease therapies. The region benefits from an established hepatology infrastructure, significant clinical research activity, and a strong presence of leading pharmaceutical companies developing NASH treatments.
The US NASH market was valued at USD 6.00 billion in 2025, driven by high prevalence of metabolic syndrome, growing demand for fibrosis assessment technologies, and increasing adoption of emerging NASH therapies. Healthcare providers are focusing on early identification and management of patients at risk of liver progression through advanced imaging and biomarker-based approaches. The country’s strong biotechnology ecosystem, extensive clinical trial network, and presence of major pharmaceutical companies continue to accelerate innovation and commercialization of NASH treatment solutions.
The NASH market in Canada was valued at USD 864.76 million in 2025, supported by expanding access to non-invasive diagnostic technologies, and growing focus on managing obesity related health conditions. The country’s publicly funded healthcare system and increasing participation in global clinical trials create opportunities for the adoption of emerging NASH therapies and advanced disease management approaches.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific: Fastest Growth Driven by Increasing Healthcare Decentralization and Increasing Diagnosis of Fatty Liver Diseases
The Asia Pacific NASH market is expected to grow at a CAGR of 25.36% during the forecast period, showcasing the fastest regional growth. Growth is supported by increasing prevalence of obesity, diabetes, and metabolic syndrome across developing economies. Growth is further driven by improving healthcare infrastructure, rising adoption of non-invasive liver diagnostics, and increasing participation in global clinical trials for NASH therapies.
The China NASH market was valued at USD 233.97 million in 2025, supported by rising burden of metabolic disorders, increasing diagnosis of fatty liver diseases, and expansion of advanced hepatology services across major healthcare centers. Government initiatives focused on chronic disease management and healthcare modernization are improving access to liver disease screening and treatment solutions. The growing presence of domestic pharmaceutical companies and increasing clinical research activities are further supporting the development and adoption of emerging NASH therapies in the country.
The India NASH market was valued at USD 119.67 million in 2025, fueled by expansion of medical tourism, increasing availability of affordable hepatology services, and rising demand for advanced liver disease management among domestic and international patients. The growth of specialized liver care centers and multispecialty hospitals is improving access to diagnosis and treatment pathways.
The Japan NASH market was valued at USD 138.08 million in 2025, supported by adoption of preventive healthcare models, integration of health screening programs with chronic disease monitoring, and greater emphasis on managing lifestyle-related conditions among the aging population. According to Japan’s Ministry of Health, Labour and Welfare, more than 60 million people participate annually in specific health checkups and health guidance programs, supporting early risk identification and disease management.
The NASH market competitive landscape is consolidated, with competition concentrated among pharmaceutical companies specializing in metabolic, hepatology, and fibrosis-targeted therapies. Leading players compete through advancements in novel drug mechanisms, strong clinical trial pipelines, and regulatory progress. Emerging biotechnology companies also focus on developing differentiated therapies targeting liver inflammation, fibrosis progression, and metabolic dysfunction. The NASH market ecosystem is shaped by increasing disease prevalence, evolving therapeutic approaches, and expanding clinical research activities.
October 2025: Novo Nordisk announced the acquisition of Akero Therapeutics to expand its MASH portfolio by adding efruxifermin (EFX), a Phase III FGF21 analogue targeting MASH with fibrosis.
September 2025: Roche announced a definitive merger agreement to acquire 89bio, strengthening its metabolic and liver disease portfolio through the addition of pegozafermin, a Phase III FGF21 analogue being developed for moderate to severe MASH.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
LAMEA Tulathromycin Market Size, Top Share, and Forecast to 2034
Complement Inhibitors Market Size, Share, Growth, Analysis, 2034
North America Aesthetic Medicine Market Size, Growth, Report to 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast to 2034
Asia Pacific Aesthetic Medicine Market Size, Top Share, Forecast to 2034
North America Multiple Electrolytes Injection Market Size by 2034
We are featured on:
sales@straitsresearch.com